Stryker CEO Kevin Lobo reported continued momentum in robotics and 3D printing technology, and told investors he was not concerned about increased competition in either field.
Edwards Lifesciences reported better-than-expected first quarter numbers behind surging sales of its transcatheter aortic valve replacement (TAVR) devices.
Galatea Surgical, a wholly owned subsidiary of Tepha Inc., announced today the FDA 510k clearance of its GalaFORM™ 3D Surgical Scaffold ("GalaFORM 3D") for use in plastic and reconstructive surgery. Based on Tepha's proprietary P4HB™ bioresorbable polymer technology, GalaFORM 3D is the only 3-dimensionally contoured, surgical scaffold with a reinforcing rim, designed to uplift the body's natural shape, provide easier placement and reduce procedure time.
Contego Medical, LLC announced today that it has received CE Marking of its Vanguard IEP™ Peripheral Balloon Angioplasty System with Integrated Embolic Protection.
Samsung, an emerging leader in medical imaging technology, announces that the GC70 Digital Radiography (DR) system received FDA 510(k) clearance for the U.S. market, underscoring the company’s commitment to expanding its suite of radiography products.
A team of Australian scientists has just completed a phase one human clinical trial with an ingestible biosensor that can measure gas produced by the gut, and potentially transmit results to a connected smartphone.
Philips' HealthTech portfolio powered the company's first quarter performance, and growth is expected to accelerate through 2017, despite weakness in the United States market related to potential healthcare policy changes.
Intuitive Surgical, a global technology leader in robotic-assisted, minimally invasive surgery, announced today that its new da Vinci X Surgical System received CE Mark approval in Europe.
joimax, the German based market leader of technologies and training methods for endoscopic minimally invasive spinal surgery, recently announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Endovapor 2 Multi Radio Frequency System.
Becton Dickinson (BD) is paying $24 billion in cash and stock to acquire C. R. Bard to move beyond diabetes care and into peripheral vascular disease, urology, hernia, and cancer treatments, as well as to round out its market-leading medication management portfolio.
|
|
|
|
|
|
|
|
|